Showing results (61-70 of 195) with videos related to

Sort By:
Pageof 20
European Heart Journal|January 10, 2019
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trialGiuseppe Boriani, Christian T Ruff, Julia F Kuder, et al.
Plos One|April 11, 2022
No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumabLaura E Korthauer, Robert P Giugliano, Jianping Guo, et al.
Circulation|July 4, 2018
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 TrialOphelia Q P Yin, Elliott M Antman, Eugene Braunwald, et al.
JACC. Clinical Electrophysiology|April 26, 2023
Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure PhenotypesRiccardo M Inciardi, Robert P Giugliano, Jeong-Gun Park, et al.
Circulation|December 28, 2018
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48David D Berg, Christian T Ruff, Petr Jarolim, et al.
International Journal of Cardiology|June 20, 2017
First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trialJan Steffel, Christian T Ruff, Rose A Hamershock, et al.
Journal of the American College of Cardiology|September 10, 2016
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 AnalysisJan Steffel, Robert P Giugliano, Eugene Braunwald, et al.
European Heart Journal|March 15, 2008
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18David A Morrow, Marc S Sabatine, Marie-Luise Brennan, et al.
International Journal of Cardiology|May 21, 2023
Neutrophil-lymphocyte ratio and clinical outcomes in 19,697 patients with atrial fibrillation: Analyses from ENGAGE AF- TIMI 48 trialAntonio Fagundes, Christian T Ruff, David A Morrow, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|February 19, 2016
Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation - An ENGAGE AF-TIMI 48 SubanalysisTakeshi Yamashita, Yukihiro Koretsune, Yuejin Yang, et al.
Pageof 20